Design Therapeutics Inc (DSGN) FinancialsDSGNDesign Therapeutics Inc

Evaluating the bottom line, Design Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.13%, provide a clear picture of how effectively DSGN converts its operational activities into shareholder value.

In the context of the broader market, DSGN competes directly with industry leaders such as PRME and SLDB. With a market capitalization of $655.86M, it holds a significant position in the sector. When comparing efficiency, DSGN's gross margin of N/A stands against PRME's 100.00% and SLDB's N/A. Such benchmarking helps identify whether Design Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has a negative net income trend, with losses increasing from -13.65 million USD in Q4 2024 to -20.17 million USD in Q2 2026. The current ratio remains strong at 18.86, suggesting good short-term liquidity.